Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals?announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship?established in 2018?with Boston Pharmaceuticals? acquisition of five GSK programs.
?This new agreement validates Boston Pharmaceuticals as a trusted development partner with whom pharmaceutical companies can collaborate,? said Robert Armstrong, Ph.D., CEO of Boston Pharmaceuticals. ?GSK has been an excellent partner and we look forward to advancing these pre-phase 2 assets into and through the clinic to evaluate their potential to improve patient lives.?
Initially, GSK will out-license and option two programs to Boston Pharmaceuticals:
- GSK3903371 - a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a tumor-associated antigen driving tumor growth and immunosuppression.
- GSK3502421 - an orally available, small molecule inhibitor for potential neurological disorders that targets Receptor Interacting Serine/Threonine Kinase 1 (RIPK1), a key component of the TNF-driven inflammation and necroptosis pathway.